Treatment News : Experimental HIV Drug Hits Snag

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 17, 2008

Experimental HIV Drug Hits Snag

Development of Koronis Pharmaceuticals’ KP-1461, an experimental antiretroviral (ARV), has been suspended after an analysis of existing data failed to show anti-HIV activity, according to a report by Project Inform. These results came as a surprise to Koronis and stand in contrast to the drug’s earlier lab studies that showed promise.

Though KP-1461 is technically a nucleoside reverse transcriptase inhibitor (NRTI), its mechanism of action is quite different from other drugs in this class of ARVs. Whereas current NRTIs are incorporated into developing DNA to stop the chains of genetic material from becoming fully formed and infectious, the integration of KP-1461 into developing chains of viral DNA causes the virus to produce defective, harmless versions of itself.

The U.S. Food and Drug Administration (FDA) had asked Koronis to do some additional lab studies to determine if HIV becomes resistant to KP-1461. During these lab studies, Koronis found that the drug had no measurable effect on HIV, a stark contrast to earlier studies that supported the drug’s clinical development. With the new results in hand, Koronis then analyzed blood samples from people enrolled in its ongoing clinical trial and, to their surprise, again found no anti-HIV activity.

Stephen Becker, MD, the lead investigator for Koronis, told Project Inform that the company is, “committed to understanding these discordant results and will attempt to validate the original 2002 research,” on KP-1461. Becker estimated that it will take at least two months to fully investigate this setback, and determine what comes next.

Search: Koronis, KP-1461, Stephen Becker, NTRI


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (6 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    TanyaB
    Delray Beach
    Florida


    sefarady
    New York
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.